Biomaterials startup Spiderwort designed the product, which uses a plant-based cellulose scaffold to promote spinal cord tissue regeneration after traumatic injuries.
The designation will “increase the speed at which we will initiate our clinical trials,” CEO and co-founder Charles Cuerrier said in a Nov. 12 announcement.
Spiderwort is preparing for a Series A financing round in 2021 as it moves closer to clinical trials.
More articles on biologics:
The most controversial trends in spine from 10 surgeons
Dr. Ali Baaj to build UArizona-Banner spine program from scratch in new role
Investment firm bets big on spine device company that rejected Stryker takeover
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
